Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Immunogenicity of Two Live Attenuated Hepatitis A Vaccines
NCT03231605Phase 4Unknown
- Sponsor
- China National Biotec Group
- Start
- Jul 2017
- Primary completion
- Aug 2017
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised trial of Hepatitis A virus vaccine in hepatitis A (HAV) (2 arms), sponsored by China National Biotec Group. Primary endpoints: Protection rate (Seroconversion rate) and Antibody Geometric Mean Titer. Status: unknown.
02
Drugs
Hepatitis A virus vaccine
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT03231605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231605.